Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder

Depression and Anxiety

Volumn 30, Issue 4, 2013, Pages 307-314

  O'Donovan, Aoife ^a,b,c,d   Rush, Gavin ^e   Hoatam, Gerard ^f   Hughes, Brian M ^g   McCrohan, Annmaria ^b   Kelleher, Cecily ^a   O'Farrelly, Cliona ^h   Malone, Kevin M ^a,b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e St Patrick's University Hospital   (Ireland)

^f CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^h TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

biological markers; depression; mood disorders; stress; suicide self harm

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENDER; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; STRUCTURED INTERVIEW; SUICIDAL IDEATION; SUICIDE ATTEMPT;

ADULT; ANALYSIS OF VARIANCE; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MIDDLE AGED; SELF-INJURIOUS BEHAVIOR; SEVERITY OF ILLNESS INDEX; SUICIDAL IDEATION; SUICIDE, ATTEMPTED; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876109471     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22087     Document Type: Article

References (44)

1. Onore C, Careaga M, Ashwood P,. The role of immune dysfunction in the pathophysiology of autism. Brain Behav Immun 2012; 26: 383-392.
2. Potvin S, Stip E, Sepehry AA, et al. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008; 63: 801-808.
3. Dantzer R, O'Connor JC, Freund GG, et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46-56.
4. Maes M, Meltzer HY, Bosmans E, et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 1995; 34: 301-309.
5. Alesci S, Martinez PE, Kelkar S, et al. Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. J Clin Endocrinol Metab 2005; 90: 2522-2530.
6. Hestad KA, Tonseth S, Stoen CD, et al. Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J ECT 2003; 19: 183-188.
7. O'Donovan A, Hughes BM, Slavich GM, et al. Clinical anxiety, cortisol and interleukin-6: evidence for specificity in emotion-biology relationships. Brain Behav Immun 2010; 24: 1074-1077.
8. Whooley MA, Caska CM, Hendrickson BE, et al. Depression and inflammation in patients with coronary heart disease: findings from the Heart and Soul Study. Biol Psychiatry 2007; 62: 314-320.
9. Glassman AH, Miller GE,. Where there is depression, there is inflammation. sometimes! Biol Psychiatry 2007; 62: 280-281.
10. O'Connor JC, Lawson MA, Andre C, et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 2009; 14: 511-522.
11. Goshen I, Kreisel T, Ben-Menachem-Zidon O, et al. Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry 2008; 13: 717-728.
12. Capuron L, Ravaud A, Gualde N, et al. Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 2001; 26: 797-808.
13. Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26: 643-652.
14. Prather AA, Rabinovitz M, Pollock BG, et al. Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality. Brain Behav Immun 2009; 23: 1109-1116.
15. Stewart JC, Rand KL, Muldoon MF, et al. A prospective evaluation of the directionality of the depression-inflammation relationship. Brain Behav Immun 2009; 23: 936-944.
16. Miller GE, Rohleder N, Stetler C, et al. Clinical depression and regulation of the inflammatory response during acute stress. Psychosom Med 2005; 67: 679-687.
17. Pace TW, Mletzko TC, Alagbe O, et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry 2006; 163: 1630-1633.
18. Dieperink E, Ho SB, Tetrick L, et al. Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psychiatry 2004; 26: 237-240.
19. Fragoso YD, Frota ER, Lopes JS, et al. Severe depression, suicide attempts, and ideation during the use of interferon beta by patients with multiple sclerosis. Clin Neuropharmacol 2010; 33: 312-316.
20. MacLeod AK, Tata P, Tyrer P, et al. Hopelessness and positive and negative future thinking in parasuicide. Br J Clin Psychol 2005; 44: 495-504.
21. O'Donovan A, Lin J, Dhabhar FS, et al. Pessimism correlates with leukocyte telomere shortness and elevated interleukin-6 in post-menopausal women. Brain Behav Immun 2009; 23: 446-449.
22. Dickerson SS, Gable SL, Irwin MR, et al. Social-evaluative threat and proinflammatory cytokine regulation: an experimental laboratory investigation. Psychol Sci 2009; 20: 1237-1244.
23. Dickerson SS, Kemeny ME,. Acute stressors and cortisol responses: a theoretical integration and synthesis of laboratory research. Psych Bull 2004; 130: 355-391.
24. Melamed S, Shirom A, Toker S, et al. Association of fear of terror with low-grade inflammation among apparently healthy employed adults. Psychosom Med 2004; 66: 484-491.
25. Tonelli LH, Stiller J, Rujescu D, et al. Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta Psychiatr Scand 2008; 117: 198-206.
26. Janelidze S, Mattei D, Westrin A, et al. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain Behav Immun 2011; 25: 335-339.
27. Lindqvist D, Janelidze S, Hagell P, et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry 2009; 66: 287-292.
28. Kim YK, Lee SW, Kim SH, et al. Differences in cytokines between non-suicidal patients and suicidal patients in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 356-361.
29. Chrousos GP,. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332: 1351-1363.
30. Pariante CM, Lightman SL,. The HPA axis in major depression: classical theories and new developments. Trends Neurosci 2008; 31: 464-468.
31. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 (Suppl 20): 22-33.
32. Hamilton M,. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
33. Tilg H, Dinarello CA, Mier JW,. IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today 1997; 18: 428-432.
34. Yasukawa H, Ohishi M, Mori H, et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 2003; 4: 551-556.
35. Maes M,. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 664-675.
36. Sublette ME, Galfalvy HC, Fuchs D, et al. Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain Behav Immun 2011; 25: 1272-1278.
37. Blascovich J, Mendes WB,. Social psychophysiology and embodiment. In:, Fiske ST, Gilbert DT, editors. The Handbook of Social Psychology. 5th ed. New York: Wiley; 2010; 194-227.
38. Hiles SA, Baker AL, de Malmanche T, et al. Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis. Psychol Medicine 2012; 1: 1-12.
39. World Health Organization Revised Global Burden of Disease (GBD); 2004. Available at: http://www.who.int/healthinfo/global-burden-disease/2004-report- update/en/index.html
40. Centers for Disease Control and Prevention, National Centers for Injury Prevention and Control. Web-based Injury Statistics Query and Reporting System (WISQARS); 2005 [cited 2012 September19]; Available at: http://www.cdc.gov/ injury/wisqars/index.html.
41. Kessler RC, Borges G, Walters EE,. Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. Arch Gen Psychiatry 1999; 56: 617-626.
42. Malone KM, Haas GL, Sweeney JA, et al. Major depression and the risk of attempted suicide. J Affect Disord 1995; 34: 173-185.
43. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey replication. Arch Gen Psychiatry 2005; 62: 593-602.
44. Warner-Schmidt JL, Vanover KE, Chen EY, et al. Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by anti-inflammatory drugs in mice and humans. Proc Natl Acad Sci USA 2011; 108: 9262-9267.